Chiesi Farmaceutici S.p.A.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-37
RECRUITING7
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| REVIVE NCT06917690 |
P3 | Recruiting | Epidermolysis Bullosa; Junctional Epidermolysis Bullosa | 6 | 2026-03 |
| TRECONY NCT07301736 |
P2 | Recruiting | Asthma | 780 | 2027-06-03 |
| RISE NCT05710692 |
P2/3 | Recruiting | Fabry Disease | 16 | 2027-10 (+19 mo) |
| Metreleptin NCT06679270 |
P3 | Recruiting | Familial Partial Lipodystrophy | 24 | 2028-03 |
| ZAPPHIRE NCT07516951 |
P2 | Recruiting | Idiopathic Pulmonary Fibrosis | 240 | 2028-06-27 |
| FLY NCT06328608 |
P2/3 | Recruiting | Fabry Disease | 22 | 2028-10 (+10 mo) |
| TRICHECO NCT07546981 |
P3 | Recruiting | Asthma | 554 | 2028-10-17 |
| FABLE NCT07577804 |
P3 | Not yet recruiting | Bronchiectasis | 904 | 2030-04 |
| TRIADES NCT07858123 |
P3 | Not yet recruiting | Asthma | 700 | 2030-06-26 |